Chemotherapy Extravasation Malpractice: Tissue Damage, Nerve Injury, and Amputation

Vesicant vs. Irritant Chemotherapy Drugs

Chemotherapy drugs are classified by their potential to cause tissue damage if they extravasate:

Vesicants (severe tissue damage): These drugs cause blistering, tissue necrosis, and potentially irreversible damage when extravasated. Common vesicant chemotherapy drugs include Doxorubicin (Adriamycin), Daunorubicin (Daunomycin), Epirubicin, Vincristine (Oncovin), Vinblastine, Vinorelbine, Mechlorethamine (nitrogen mustard), Dactinomycin (Actinomycin D), and Mitomycin C.

Exfoliants (moderate tissue damage): These drugs cause skin exfoliation (peeling) but are less likely to cause deep necrosis. Examples include Docetaxel (Taxotere), Paclitaxel (Taxol), Cisplatin, Carboplatin, and Oxaliplatin.

Irritants (mild tissue damage): These drugs cause local inflammation, pain, and phlebitis (vein inflammation) but typically do not cause tissue necrosis. Examples include 5-Fluorouracil (5-FU), Bleomycin, Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide.

How Extravasation Happens

Extravasation can occur due to several mechanisms, many of which involve preventable errors:

- IV catheter dislodgement: The IV catheter moves out of the vein during chemotherapy infusion, allowing the drug to infuse into surrounding tissue. - Vessel wall damage: The needle punctures the opposite wall of the vein, or the catheter erodes through the vessel wall over time. - Improper IV placement: Inserting an IV in a high-risk location — such as the antecubital fossa (inner elbow), wrist, or hand — where movement and joint flexion increase the risk of dislodgement. Vesicant chemotherapy should ideally be administered through a central venous catheter or a newly placed peripheral IV in the forearm. - Failure to verify IV patency: Before administering vesicant chemotherapy, the nurse must verify that the IV is patent (properly positioned in the vein with good blood return). Failure to check blood return before and during vesicant administration is a deviation from the standard of care. - Failure to recognize extravasation signs: Patients may report pain, burning, or swelling at the IV site. The nurse must stop the infusion immediately and assess. Ignoring patient complaints of pain during vesicant administration is a serious deviation from the standard of care. - Inadequate staffing or monitoring: Chemotherapy should be administered by oncology-certified nurses with specific training in extravasation prevention and management. Delegation to inadequately trained staff is negligence.

Preventing Extravasation: Standard of Care

The Oncology Nursing Society (ONS) and the American Society of Clinical Oncology (ASCO) have established clear standards for preventing chemotherapy extravasation. The standard of care requires:

- Proper IV site selection: Vesicant chemotherapy should be administered through a central venous access device (port, PICC line) or a newly placed, large-bore peripheral IV in the forearm — not in the hand, wrist, or antecubital fossa. - Verify IV patency: Before administering vesicant chemotherapy, the nurse must verify blood return and confirm that the IV flushes easily without resistance or swelling. - Monitor continuously: The nurse must monitor the IV site throughout the infusion and assess for signs of extravasation (swelling, redness, pain, decreased flow rate). - Respond to patient complaints: If the patient reports pain, burning, or discomfort at the IV site, the infusion must be stopped immediately and the site assessed. - Use of central lines for vesicants: When possible, vesicant chemotherapy should be administered through a central venous catheter to eliminate the risk of peripheral extravasation. - Patient education: Patients should be educated to report immediately any pain, burning, or discomfort at the IV site during chemotherapy. - Adequate training: Only oncology-certified nurses with specific chemotherapy administration training should administer vesicant drugs.

Consequences of Chemotherapy Extravasation

The consequences of vesicant chemotherapy extravasation can be devastating and permanent:

• Tissue necrosis: Vesicant drugs cause progressive tissue death that can extend deeply through skin, fat, muscle, and tendon. The necrosis may continue to progress for weeks after the initial injury as the drug continues to damage surrounding cells.
• Deep tissue and tendon injury: Extravasation in the hand or wrist can cause damage to tendons, ligaments, and joints, resulting in permanent functional impairment of the hand or arm.
• Nerve damage: Nerves in the surrounding tissue can be damaged, causing chronic pain, numbness, and weakness (neuropathic pain, complex regional pain syndrome).
• Infection: Necrotic tissue is prone to infection, including necrotizing fasciitis and sepsis, which can be life-threatening.
• Amputation: In severe cases, extensive tissue necrosis may necessitate amputation of fingers, hand, or arm.
• Functional impairment: Even without amputation, scarring, contractures, and nerve damage can permanently impair use of the affected limb.
• Delayed cancer treatment: Extravasation injuries may delay or interrupt the patient's cancer treatment, potentially affecting prognosis.
• Psychological trauma: Cancer patients already under enormous stress may suffer additional psychological harm from a preventable treatment-related injury.

When Extravasation Constitutes Malpractice

Chemotherapy extravasation constitutes medical malpractice when the healthcare provider's conduct fell below the standard of care and caused tissue injury. Common malpractice scenarios include:

- Improper IV site selection: Administering a vesicant chemotherapy drug through an IV in the hand, wrist, or antecubital fossa — where joint movement increases the risk of dislodgement. - Failure to verify IV patency: Not checking for blood return before or during vesicant administration. - Failure to use a central line: When a central venous access device was available and appropriate but not used for vesicant administration. - Ignoring patient complaints: Failing to stop the infusion when the patient reported pain, burning, or swelling. - Inadequate monitoring: Leaving the infusion unattended or infusing vesicant drugs over a prolonged period without checking the site. - Delayed treatment: Not recognizing extravasation promptly or failing to administer the appropriate antidote (e.g., dexrazoxane for anthracycline extravasation) within the required time window (typically within 6 hours). - Inadequate documentation: Failure to document IV site assessment, blood return verification, and patient education — which may itself be evidence of substandard care.

Expert testimony from an oncology nurse or oncologist is required to establish the standard of care and demonstrate how it was breached.

Treatment and Reconstruction

Treatment of chemotherapy extravasation depends on the drug and severity: - Immediate steps: Stop the infusion, aspirate any remaining drug from the IV catheter, and remove the catheter. Apply cold or warm compresses depending on the drug (cold for most vesicants, warm for vinca alkaloids). - Antidotes: Specific antidotes may be administered. For example, dexrazoxane (Totect, Savene) is the FDA-approved antidote for anthracycline (doxorubicin, daunorubicin, epirubicin) extravasation and must be administered within 6 hours. Hyaluronidase may be used for vinca alkaloid extravasation. - Surgical debridement: If tissue necrosis develops, surgical removal of dead tissue (debridement) may be necessary to prevent infection and promote healing. - Reconstructive surgery: Skin grafting, flap reconstruction, or tendon repair may be needed to restore function and appearance. - Rehabilitation: Physical and occupational therapy to restore limb function after severe extravasation injuries.

Failure to administer the appropriate antidote within the required time window — or failure to refer for surgical evaluation when necrosis is developing — may itself constitute negligence.

New York Malpractice Law

Chemotherapy extravasation malpractice cases in New York are governed by: - CPLR § 214-a: 2.5-year statute of limitations from the date of the extravasation event. - CPLR § 3012-a: Certificate of merit requirement. - CPLR § 208: Infancy toll for minors. - EPTL § 5-4.1: Wrongful death statute — if the patient died from extravasation complications (sepsis, amputation complications).

Liable parties may include the oncology nurse who administered the chemotherapy, the oncologist who ordered it, the infusion center or hospital, and the institution responsible for chemotherapy administration policies. New York does not cap non-economic damages — critical in extravasation cases where permanent disfigurement, nerve damage, and loss of limb function are primary damages.

Frequently Asked Questions

The value of a medical malpractice case in New York depends on several factors, including the severity of the injury, the strength of liability evidence, and the economic and non-economic damages involved. New York is one of the few states with no caps on medical malpractice damages, meaning there is no artificial limit on what you can recover. Below are typical settlement ranges based on injury severity.